Business Context and Reporting Period
This Form 6-K is filed by pSivida Limited, a foreign issuer, for the month of March 2005. The report was signed on March 30, 2005, by Aaron Finlay, Chief Financial Officer and Company Secretary. The company is headquartered in Perth, Western Australia.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a corporate event rather than a financial statement.
Material Changes
The primary material change reported is a milestone achievement in the production scale-up process for the company's BrachySilTM cancer therapy product.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a detailed discussion of risks and contingencies beyond the context of the production milestone. No unusual items were disclosed in the provided text.
Key Facts for Investor Verification
- Verify the specific technical details and timeline implications of the BrachySilTM production scale-up milestone.
- Confirm the current regulatory status of BrachySilTM in relevant markets.
- Review subsequent filings for financial impact resulting from this production milestone.